<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349934</url>
  </required_header>
  <id_info>
    <org_study_id>P005</org_study_id>
    <secondary_id>Umanis-CRO0425</secondary_id>
    <nct_id>NCT00349934</nct_id>
  </id_info>
  <brief_title>IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma</brief_title>
  <official_title>IMP321 Phase I Study in Metastatic Breast Carcinoma Patients Receiving First-line Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immutep S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Umanis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immutep S.A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory&#xD;
      setting in patients receiving as a first line chemotherapy for metastatic breast carcinoma&#xD;
      the standard 6 cycles of weekly paclitaxel (80 mg/m² at D1, D8 and D15 of a 4-week cycle).&#xD;
      Three IMP321 doses (0.25, 1.25 and 6.25 mg) will be tested and given at D2 and D16 of this&#xD;
      4-week cycle, for 6 courses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, non-randomized, fixed dose-escalation phase I study, performed&#xD;
      in ambulatory setting with patients receiving as a first line chemotherapy for metastatic&#xD;
      breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every&#xD;
      4-week cycle). Twenty mg i.v. dexamethasone will be given in the first cycle before each&#xD;
      paclitaxel infusion. Corticosteroids will not be administered after the first chemotherapy&#xD;
      cycle if the first 3 i.v. infusions of paclitaxel have been well tolerated.&#xD;
&#xD;
      Three IMP321 dose levels (0.25, 1.25 and 6.25 mg) will be evaluated in three cohorts of at&#xD;
      lesat 8 patients. At any given dose level the patients will be administered one dose every&#xD;
      two weeks for a total of 24 weeks (12 injections in total), separated by 13-day intervals&#xD;
      free of IMP321 administration.&#xD;
&#xD;
      The study drug will be given by subcutaneous injection:&#xD;
&#xD;
        -  Cohort A: 0.25 mg s.c.&#xD;
&#xD;
        -  Cohort B: 1.25 mg s.c.&#xD;
&#xD;
        -  Cohort C: 6.25 mg s.c.&#xD;
&#xD;
      The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day&#xD;
      which follows chemotherapy.&#xD;
&#xD;
      After a screening performed between Week -2 and Day 1, patients will enter the main study&#xD;
      period. Upon having completed the 6 cycles of IMP321 treatment at Week 23, they will have an&#xD;
      ambulatory 'post-study' examination (at Week 25).&#xD;
&#xD;
      Cohort B will be undertaken once the safety and tolerability results of Cohort A have been&#xD;
      satisfactory; the investigator will take his decision for involving the last 8 patients of&#xD;
      the study after the 6th administration (Week 13 assessment) of the fifth patient of Cohort A.&#xD;
      All cohorts will follow the same schedule&#xD;
&#xD;
      Standard clinical and laboratory safety examinations, CT scan and pharmacodynamic (PD) blood&#xD;
      tests will be performed. A complete examination will be carried out at Week 13 (after the 6th&#xD;
      drug dosing) and Week 25.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate clinical and laboratory safety and tolerability profiles</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine pharmacodynamic parameters</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (OR) using RECIST criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMP321</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMP321</intervention_name>
    <description>This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).&#xD;
Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.&#xD;
The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>LAG-3</other_name>
    <other_name>hLAG-3Ig</other_name>
    <other_name>CD223</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stage IV breast adenocarcinoma, histologically proven by biopsy of the&#xD;
             primary tumor and/or a metastasis.&#xD;
&#xD;
          -  Female not pregnant (or with negative pregnancy test) or male.&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after drug&#xD;
             administration.&#xD;
&#xD;
          -  18 years or above.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Expected survival longer than three months.&#xD;
&#xD;
          -  Resolution of toxicity of prior therapy to grade &lt; 2 (except alopecia).&#xD;
&#xD;
          -  With or without prior adjuvant or neoadjuvant chemotherapy (authorized).&#xD;
&#xD;
          -  With or without hormone therapy in adjuvant and/or the advanced setting (authorized).&#xD;
&#xD;
          -  Evidence of measurable disease as defined by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST).&#xD;
&#xD;
          -  Biphosphonate therapy must have started at least 4 weeks prior to first dosing of the&#xD;
             study drug.&#xD;
&#xD;
          -  Asthma or chronic obstructive pulmonary disease allowed provided daily systemic&#xD;
             corticosteroid therapy is not required.&#xD;
&#xD;
          -  Total white cell count ≥ 3.109/L.&#xD;
&#xD;
          -  Platelet count ≥ 100.109/L.&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL or &gt; 5.58 mmol/L.&#xD;
&#xD;
          -  Serum creatinine &lt; 160 µmol/L.&#xD;
&#xD;
          -  Total bilirubin &lt; 20 mmol/L, except for familial cholemia (Gilbert's disease).&#xD;
&#xD;
          -  Serum ASAT and ALAT &lt; 3 times the upper limit of normal or &lt; 5 times upper limit of&#xD;
             normal if liver metastases are present.&#xD;
&#xD;
          -  Able to give written informed consent and to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy for metastatic breast adenocarcinoma.&#xD;
&#xD;
          -  Disease-free interval &lt; 12 months from last dose of adjuvant chemotherapy.&#xD;
&#xD;
          -  Prior high-dose chemotherapy requiring hematopoietic stem cell rescue.&#xD;
&#xD;
          -  Inflammatory carcinoma.&#xD;
&#xD;
          -  Systemic chemotherapy, hormone or endocrine therapy given as breast cancer therapy&#xD;
             within 30 days prior to first dosing of the study drug.&#xD;
&#xD;
          -  Any investigational drug within 30 days prior to first dosing of the study drug.&#xD;
&#xD;
          -  Candidate for treatment with trastuzumab or administration of trastuzumab within 30&#xD;
             days prior to first dosing of the study drug.&#xD;
&#xD;
          -  Known cerebral or leptomeningeal metastases.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Serious intercurrent infection within the 30 days prior to first dosing of the study&#xD;
             drug.&#xD;
&#xD;
          -  Motor or sensory peripheral neuropathy ≥ 2 according to the National Cancer Institute&#xD;
             criteria.&#xD;
&#xD;
          -  Congestive heart failure.&#xD;
&#xD;
          -  Active acute or chronic infection.&#xD;
&#xD;
          -  Active autoimmune disease requiring immunosuppressive therapy.&#xD;
&#xD;
          -  Known HIV positivity.&#xD;
&#xD;
          -  Life threatening illness unrelated to cancer.&#xD;
&#xD;
          -  Previous malignancies within the last two years other than breast carcinoma,&#xD;
             successfully treated squamous cell carcinoma of the skin or in situ carcinoma of the&#xD;
             cervix treated with cone biopsy.&#xD;
&#xD;
          -  Previous history of major psychiatric disorder requiring hospitalization or any&#xD;
             current psychiatric disorder that would impede the patient's ability to provide&#xD;
             informed consent or to comply with the protocol.&#xD;
&#xD;
          -  Corticosteroids unless used as substitutive therapy or before each injection of&#xD;
             paclitaxel.&#xD;
&#xD;
          -  Past history of severe allergic episodes and/or Quincke edema.&#xD;
&#xD;
          -  Past or present history of any organic disorder likely to modify absorption,&#xD;
             distribution or elimination of the study drug.&#xD;
&#xD;
          -  Alcohol or substance abuse disorder.&#xD;
&#xD;
          -  Radiotherapy within the 30 days prior to first dosing of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maya Gutierrez, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre René Huguenin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.immutep.com</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>July 7, 2006</study_first_submitted>
  <study_first_submitted_qc>July 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>F. Triebel, Chief Medical Officer</name_title>
    <organization>Immutep S.A.</organization>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>IMP321</keyword>
  <keyword>hLAG-3Ig</keyword>
  <keyword>LAG-3</keyword>
  <keyword>CD223</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

